截至7月17日收盘，重组蛋白概念上涨2.92%，位居概念板块涨幅第7，板块内，43股上涨，成都先导、 迈威生物等20%涨停，神州细胞、海特生物、科兴制药等涨幅居前，分别上涨15.40%、11.93%、 10.14%。跌幅居前的有ST未名、*ST苏吴、丽珠集团等，分别下跌5.01%、4.81%、0.49%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 兵装重组概念 | 4.22 | 房屋检测 | -0.18 | | 同花顺果指数 | 3.37 | 黄金概念 | -0.13 | | 共封装光学(CPO) | 3.34 | 举牌 | -0.12 | | PCB概念 | 3.07 | 水泥概念 | -0.06 | | AI手机 | 3.01 | 固废处理 | -0.03 | | AI PC | 3.01 | 新型城镇化 | -0.03 | | 重组蛋白 | 2.92 | ST板块 | -0.01 | | 海南自贸区 | 2.76 | 猪肉 | 0.00 | | 创新药 | 2.68 | 大豆 | 0.01 | | ...

迈威生物7月17日龙虎榜 | 买入营业部名称 | 买入金额(万元) | | --- | --- | | 沪股通专用 | 11811.78 | | 华鑫证券有限责任公司江苏分公司 | 2740.40 | | 中信证券股份有限公司上海分公司 | 2602.12 | | 机构专用 | 2410.03 | | 东海证券股份有限公司福州长乐北路证券营业部 | 2104.20 | | 卖出营业部名称 | 卖出金额(万元) | | 机构专用 | 8839.24 | | 沪股通专用 | 5312.46 | | 海通证券股份有限公司上海临港分公司 | 4297.52 | | 海通证券股份有限公司深圳红岭北路证券营业部 | 2501.55 | | 华鑫证券有限责任公司深圳福田分公司 | 2184.16 | 7月17日迈威生物（688062）收盘价37.33元，收盘涨停，全天换手率17.80%，振幅19.27%，成交额 12.69亿元。科创板交易公开信息显示，当日该股因日收盘价涨幅达15%等上榜。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交4.48亿元， 其中，买入成交额为2.17亿 元，卖出成交额为2.31亿元，合 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 7月17日，高股息资产延续回调走势，市场的天平再次倾向了创新药、算力、军工等赛道，赚钱效应出 现明显好转。 截至收盘，上证指数涨0.37%，报3516.83点；深证成指涨1.43%，报10873.62点；创业板指涨1.75%，报 2269.33点。 值得一提的是，在A股市场走高之际，外资看多的声音逐渐增多。景顺全球主权资产管理研究最新发布 显示，国际投资机构对中国市场的兴趣明显回升。韩国证券存托结算院（KSD）最新数据也显示，截至 7月15日，今年以来韩国投资者对中国内地与香港股市的累计交易额已超过54亿美元，中国市场成为韩 国股民的第二大海外投资目的地，仅次于美国市场。 赛道股全线爆发 创新药概念延续强势，维康药业（维权）、迈威生物实现20%涨停，首药控股、神州细胞、复旦张江等 多股上涨超10%。 | 股份 | 大事 | 资讯 | 公告 | 研究报告 | 贡献点数 | | | --- | --- | --- | --- | --- | --- | --- | | 代码 | | 名称 | * ● | 最新 | 张唱歌下 | 金额 | | ...

迈威生物今日20CM涨停，成交额12.69亿元，换手率17.80%，盘后龙虎榜数据显示，沪股通专用席位买 入1.18亿元并卖出5312.46万元，一机构专用席位净买入2410.03万元，另有一机构专用席位净卖出 8839.24万元。 ...

从消息面来看，近期，创新药板块的利好消息不断。接下来，这个板块的行情是否会持续下去呢？ 创新药概念股集体爆发 自6月底以来，创新药板块一路上行，最近几天更是加速上涨。7月17日，创新药板块指数涨幅超过3%，成都 先导、迈威生物、维康药业、塞力医疗、力生制药、亚太药业、信立泰等近20只相关概念股涨停或涨超10%。 7月17日，创新药领域又传来一则好消息。据北京日报报道，近日，我国自主研发的、抗呼吸道合胞病毒的创 新药——齐瑞索韦列入世界卫生组织儿童药物优化优先清单，有望为全球儿童带来可及、可负担的有效治疗。 据报道，世界卫生组织儿童药物优化（PADO）项目通过凝聚监管机构、资助方与制造商共识，推动有紧迫需 求的儿童药物加速开发，工作内容包括确定研发的重点优先产品及其理想的产品特性。 创新药板块，再次掀起涨停潮！ 今日（7月17日），A股三大指数集体拉升，截至收盘，沪指涨0.37%，深证成指涨1.43%，创业板指涨1.76%。 盘面上，创新药、CPO、AI硬件等方向领涨。其中，创新药概念股集体大涨，成都先导、塞力医疗、力生制药 等近20只相关概念股涨停或涨超10%。 在港股市场上，创新药概念股也集体爆发，截至收盘 ...

Group 1 - Several A-share listed companies, including Shijia Photon, Oriental Bio, and Maiwei Bio, have disclosed their latest top ten shareholders due to buyback activities, revealing adjustments by well-known fund managers [1][2] - Notable fund managers such as Jin Zicai, Wan Minyuan, and Jin Xiaofei have made significant adjustments in their holdings, with Jin Zicai's funds entering the top ten shareholders of Shijia Photon after a 130% increase in its stock price in the first half of the year [2] - Foreign institutions like Barclays, UBS, and JPMorgan have increased their stakes in several A-share companies, indicating growing foreign interest in the market [3] Group 2 - The A-share market is experiencing structural opportunities amid internal and external factors, with a potential upward trend in the short term [4] - The overall investment attractiveness of the Chinese capital market is improving, with an increase in stock buybacks and dividend distributions, which are highly valued by foreign investors [4][5] - Economic indicators show signs of recovery in consumption, investment, and exports, with expectations for a more accommodative monetary policy in the coming quarters [5]

迈威（上海）生物科技股份有限公司 2025 年第一次临时股东大会会议资料 2025 年 7 月 | 6 | | --- | 迈威（上海）生物科技股份有限公司 2025 年第一次临时股东大会会议须知 为了维护全体股东的合法权益，保证股东在迈威（上海）生物科技股份有 限公司（以下简称"公司"）依法行使股东权利，确保 2025 年第一次临时股东 大会会议的正常秩序和议事效率，根据《中华人民共和国公司法》（以下简称 "《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）、 中国证券监督管理委员会（以下简称"中国证监会"）《上市公司股东大会规 则》以及《迈威（上海）生物科技股份有限公司公司章程》（以下简称"《公 司章程》"）《迈威（上海）生物科技股份有限公司股东大会议事规则》等有 关规定，特制定本须知，请全体出席股东大会的人员自觉遵守。 二、 经公司审核后符合参加本次股东大会条件的股东（含股东代理人）、 董事、监事、高级管理人员及其他出席人员方可出席本次会议；公司有权拒绝 不符合条件的人士进入会场。 三、 会议按照会议通知上所列顺序审议、表决议案。 四、 股东及股东代理人依法享有发言权、质询权、表决权等权利 ...

Group 1 - In July, private equity institutions showed strong interest in A-share listed companies, with 751 institutions participating in research covering 387 companies, totaling 1,769 research instances [1][5] - The electronic industry led the research focus with 275 instances involving 56 companies, followed by the pharmaceutical and biological industry with 266 instances covering 41 companies [1][5] - The technology growth sector is experiencing increasing enthusiasm, with significant capital inflows into technology-themed ETFs, indicating a positive outlook for AI-related industries [3] Group 2 - Insurance capital has been actively acquiring stakes in listed companies, with 19 instances of stake acquisitions involving 15 companies this year, indicating a trend towards long-term stable investment returns [5] - The banking sector is facing challenges due to narrowing net interest margins, prompting banks to enhance their intermediary business development, with wealth management and financial investment seen as growth areas [3] - A-share buyback enthusiasm remains high, with notable companies like China Communications Construction planning significant buybacks, reflecting a strategic move to bolster market confidence [9]

Group 1 - The Shanghai Stock Exchange has released the "Self-Regulatory Supervision Guidelines for Companies Listed on the Sci-Tech Innovation Board No. 5 - Sci-Tech Growth Tier" [1] - The reform does not impose additional listing thresholds for unprofitable companies entering the Sci-Tech Growth Tier, allowing 32 existing unprofitable companies to enter immediately upon the guideline's implementation [1] - Newly registered unprofitable companies will enter the Sci-Tech Growth Tier from the date of their listing [1] Group 2 - Investors participating in the subscription and trading of newly registered stocks in the Sci-Tech Growth Tier must sign a "Risk Disclosure Statement for the Sci-Tech Growth Tier" [2] - The 32 existing companies that have not yet removed the "U" designation include: Zejing Pharmaceutical, Junshi Biosciences, Frontier Biotech, Qingyun Technology, Hehui Optoelectronics, Jingjin Electric, BeiGene, Dize Pharmaceutical, Maiwei Biotech, Aojie Technology, Yuhong Pharmaceutical, Shouyao Holdings, Haichuang Pharmaceutical, CloudWalk Technology, Yifang Biotech, Obsidian Optics, Mengke Pharmaceutical, Nuo Cheng Jianhua, Xinke Mobile, Xinghuan Technology, Yutai Micro, Yuntian Lifa, Tianzhihang, Qi Anxin, Hanwujin, Yihua Tong, Aifute, Huizhiwei, Xinlian Integrated, Zhixiang Jintai, Shengke Communication, and Zhongjuxin [2]

Group 1 - Foreign-funded public fund institutions in China have launched 31 new fund products in the first half of the year, with a total new issuance scale of 35.88 billion, representing a 138% increase in quantity and a 43% increase in scale compared to the same period last year [2] - The cold chain logistics market in China is showing positive development, with a total demand for food cold chain logistics expected to reach approximately 192 million tons in the first half of the year, a year-on-year increase of 4.35% [2] - The total logistics value for cold chain logistics in China is projected to be around 4.7 trillion yuan, reflecting a year-on-year growth of 4.21% [2] Group 2 - The largest natural uranium production project in China, "Guo Uranium No. 1" demonstration project, successfully produced its first barrel of uranium, marking a significant breakthrough in domestic uranium production [3] - Over 40 stocks will face unlocking next week, with a total unlocking market value exceeding 27 billion yuan, including Tianyue Advanced with an unlocking market value of 7.487 billion yuan [3] Group 3 - NVIDIA's CEO Jensen Huang has sold approximately 225,000 shares of the company, valued at around 36.4 million dollars, as part of a stock sale plan allowing him to sell up to 6 million shares by the end of the year [5] - Google has agreed to pay approximately 2.4 billion dollars for the technology licensing of AI coding startup Windsurf and has hired its CEO and some employees [5]